

Remarks

Status of the Claims

Prior to the entry of this amendment, claims 1-20, 29-45, and 54-71 were pending in the application. Claims 21-28 and 46-53 were previously canceled. Claims 1-20, 29-45, and 54-57 have been withdrawn pursuant to a restriction requirement. Applicants hereby cancel claims 1-20, 29-45, and 54-57 without prejudice and reserve the right to pursue unclaimed subject matter in subsequent applications.

Claims 58, 60, 62-66, and 68-71 have been allowed. Claims 59, 61 and 67 are pending and currently under consideration.

Rejections under 35 U.S.C. § 112, first paragraph

Claims 59, 61, and 67 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the written description requirement. The Examiner alleges that the application “presents a claim for subject matter not originally claimed or embraced in the statement of the invention.” Office Action of 08/29/05, p.2. In particular, the Examiner alleges the list of inflammatory diseases and conditions to be treated with the methods of the invention is not disclosed in the specification, and contends the application only “indicates a role for selectin-mediated cellular adhesion in the processes of inflammation, thrombotic disorders, parasitic disorders, and possibly the metastatic spread of tumor cells (p. 1, lines 20-25), but does not conceive the diseases presented in the claims.” *Id.*

On the contrary, Applicants respectfully direct the Examiner to paragraph 97 of the published application (p. 21, line 34 to p. 22, line 19 of the specification as-filed),

which states:

Isolated P-selectin ligand protein may be useful in treating conditions characterized by P-, E- or L-selectin mediated intercellular adhesion. Such conditions include, without limitation, myocardial infarction, bacterial or viral infection, metastatic conditions, inflammatory disorders such as arthritis, gout, uveitis, acute respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythematosus, thermal injury such as burns or frostbite, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, multiple organ injury syndrome secondary to trauma, diabetes, Reynaud's syndrome, neutrophilic dermatosis (Sweet's syndrome), inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, necrotizing enterocolitis, granulocyte transfusion associated syndrome, cytokine-induced toxicity, and the like. . . . Isolated P-selectin ligand protein may be used to treat hemodialysis and leukophoresis patients. Additionally, isolated P-selectin ligand protein may be used as an antimetastatic agent. Isolated P-selectin ligand protein may be used itself as an inhibitor of P-, E- or L-selectin-mediated intercellular adhesion or to design inhibitors of P-, E- or L-selectin-mediated intercellular adhesion.

This section clearly provides adequate written description support for the additional inflammatory diseases included in claims 59, 61, and 67. Accordingly, Applicants respectfully request that the instant rejection be withdrawn.

CONCLUSION

In view of the foregoing remarks, Applicants respectfully request withdrawal of this rejection and timely allowance of the pending claims. Should the Examiner have remaining questions or concerns regarding this application, Applicants request that the

Examiner contact the undersigned at 202-408-4086 to schedule an interview to discuss the application.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 21, 2005

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796